{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:46:26Z","timestamp":1792273586831,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00198-026-08020-7","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:23:30Z","timestamp":1776407010000},"page":"1979-1990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased osteoporosis burden and comparative antiresorptive effectiveness in inflammatory bowel disease: a real-world cohort study"],"prefix":"10.1007","volume":"37","author":[{"given":"Aakash","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-7277","authenticated-orcid":false,"given":"Himsikhar","family":"Khataniar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G.","family":"Hashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursimran S.","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"3","key":"8020_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/mi.2017.18","volume":"10","author":"KG Lassen","year":"2017","unstructured":"Lassen KG, Xavier RJ (2017) Genetic control of autophagy underlies pathogenesis of inflammatory bowel disease. Mucosal Immunol 10(3):589\u2013597. https:\/\/doi.org\/10.1038\/mi.2017.18","journal-title":"Mucosal Immunol"},{"issue":"1","key":"8020_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, Sadeghi A, Nixon MR, Abdoli A, Abolhassani H, Alipour V (2020Jan 1) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet gastroenterology & hepatology. 5(1):17\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(19)30333-4","journal-title":"The Lancet gastroenterology & hepatology."},{"issue":"10","key":"8020_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrgastro.2013.152","volume":"10","author":"C Ott","year":"2013","unstructured":"Ott C, Sch\u00f6lmerich J (2013) Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 10(10):585\u2013595. https:\/\/doi.org\/10.1038\/nrgastro.2013.152","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"8020_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/1744666X.2020.1767749","volume":"16","author":"L Peyrin-Biroulet","year":"2020","unstructured":"Peyrin-Biroulet L, Greuter T, Rieder F et al (2020) Emerging treatment options for extra-intestinal manifestations in inflammatory bowel disease. Expert Rev Clin Immunol 16(7):707\u2013720. https:\/\/doi.org\/10.1080\/1744666X.2020.1767749","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"8020_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.amjmed.2009.02.032","volume":"122","author":"T Ali","year":"2009","unstructured":"Ali T, Lam D, Bronze MS, Humphrey MB (2009) Osteoporosis in inflammatory bowel disease. Am J Med 122(7):599\u2013604. https:\/\/doi.org\/10.1016\/j.amjmed.2009.02.032","journal-title":"Am J Med"},{"key":"8020_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133748","volume":"10","author":"MS Tsai","year":"2015","unstructured":"Tsai MS, Hsu CW, Wang YC et al (2015) Increased risk of osteoporosis in patients with inflammatory bowel disease: a nationwide population-based study. PLoS ONE 10:e0133748. https:\/\/doi.org\/10.1371\/journal.pone.0133748","journal-title":"PLoS ONE"},{"issue":"9","key":"8020_CR7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/j.1572-0241.1998.00512.x","volume":"93","author":"RD Pollak","year":"1998","unstructured":"Pollak RD, Karmeli F, Eliakim R et al (1998) Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 93(9):1483\u20131490. https:\/\/doi.org\/10.1111\/j.1572-0241.1998.00512.x","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"8020_CR8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.14309\/ajg.0000000000003541","volume":"120","author":"FA Farraye","year":"2025","unstructured":"Farraye FA, Melmed GY, Lichtenstein GR et al (2025) ACG clinical guideline update: preventive care in inflammatory bowel disease. Am J Gastroenterol 120(7):1447\u20131473. https:\/\/doi.org\/10.14309\/ajg.0000000000003541","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"8020_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cgh.2017.10.007","volume":"16","author":"P Szafors","year":"2018","unstructured":"Szafors P, Che H, Barnetche T et al (2018) Risk of fracture and low bone mineral density in adult inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 16(5):630-639.e8. https:\/\/doi.org\/10.1016\/j.cgh.2017.10.007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"8020_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/j.1572-0241.2006.00673.x","volume":"101","author":"A Kornbluth","year":"2006","unstructured":"Kornbluth A, Hayes M, Feldman S et al (2006) Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease patients. Am J Gastroenterol 101(7):1546\u20131550. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00673.x","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"8020_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00198-019-05184-4","volume":"31","author":"AA van Bodegraven","year":"2020","unstructured":"Bodegraven AA, Bravenboer N (2020) Perspective on skeletal health in inflammatory bowel disease. Osteoporos Int 31(4):637\u2013646. https:\/\/doi.org\/10.1007\/s00198-019-05184-4","journal-title":"Osteoporos Int"},{"issue":"2","key":"8020_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jocd.2019.05.018","volume":"23","author":"VG Chedid","year":"2020","unstructured":"Chedid VG, Kane SV (2020) Bone health in patients with inflammatory bowel diseases. J Clin Densitom 23(2):182\u2013189. https:\/\/doi.org\/10.1016\/j.jocd.2019.05.018","journal-title":"J Clin Densitom"},{"issue":"6","key":"8020_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/nu12061702","volume":"12","author":"AE Ratajczak","year":"2020","unstructured":"Ratajczak AE, Rychter AM, Zawada A et al (2020) Nutrients in the prevention of osteoporosis in patients with inflammatory bowel diseases. Nutrients 12(6):1702. https:\/\/doi.org\/10.3390\/nu12061702","journal-title":"Nutrients"},{"issue":"4","key":"8020_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00198-023-06945-8","volume":"35","author":"L Kreienbuehl","year":"2024","unstructured":"Kreienbuehl L, Zeitz J, Scharl M et al (2024) Perspective on skeletal health in inflammatory bowel disease. Osteoporos Int 35(4):789\u2013802. https:\/\/doi.org\/10.1007\/s00198-023-06945-8","journal-title":"Osteoporos Int"},{"issue":"11","key":"8020_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M16-2415","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Forciea MA, McLean RM, Denberg TD (2017) Treatment of low bone density or osteoporosis to prevent fractures: an ACP clinical practice guideline update. Ann Intern Med 166(11):818\u2013839. https:\/\/doi.org\/10.7326\/M16-2415","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"8020_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP-2020-0011","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) AACE\/ACE clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update. Endocr Pract 26(Suppl 1):1\u201346. https:\/\/doi.org\/10.4158\/EP-2020-0011","journal-title":"Endocr Pract"},{"issue":"1","key":"8020_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1572-0241.2005.00380.x","volume":"101","author":"S Henderson","year":"2006","unstructured":"Henderson S, Hoffman N, Prince R (2006) A double-blind placebo-controlled study of risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 101(1):119\u2013123. https:\/\/doi.org\/10.1111\/j.1572-0241.2005.00380.x","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"8020_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cgh.2013.08.024","volume":"12","author":"J Melek","year":"2014","unstructured":"Melek J, Sakuraba A (2014) Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol 12(1):32-44.e5. https:\/\/doi.org\/10.1016\/j.cgh.2013.08.024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8020_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.07002.x","volume":"1277","author":"C Goessl","year":"2012","unstructured":"Goessl C, Katz L, Dougall WC et al (2012) Development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann N Y Acad Sci 1277:1\u201312. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.07002.x","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"8020_CR20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz322","volume":"105","author":"T Diker-Cohen","year":"2020","unstructured":"Diker-Cohen T, Rosenberg D, Avni T et al (2020) Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab 105(5):dgz322. https:\/\/doi.org\/10.1210\/clinem\/dgz322","journal-title":"J Clin Endocrinol Metab"},{"key":"8020_CR21","volume-title":"Prolia\u00ae (denosumab) injection, prescribing information","author":"U.S. Food and Drug Administration","year":"2010","unstructured":"U.S. Food and Drug Administration (2010) Prolia\u00ae (denosumab) injection, prescribing information. FDA, Silver Spring, MD"},{"issue":"5","key":"8020_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/ibd\/izac131","volume":"29","author":"S Hutfless","year":"2023","unstructured":"Hutfless S, Jasper RA, Tilak A et al (2023) A systematic review of Crohn\u2019s disease case definitions in administrative or claims databases. Inflamm Bowel Dis 29(5):705\u2013715. https:\/\/doi.org\/10.1093\/ibd\/izac131","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"8020_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae251","volume":"31","author":"GS Kochhar","year":"2024","unstructured":"Kochhar GS, Khataniar H, Hashash JG et al (2024) Comparative effectiveness of ozanimod and vedolizumab as first-line advanced therapies in ulcerative colitis: a propensity-matched cohort analysis. Inflamm Bowel Dis ae251. https:\/\/doi.org\/10.1093\/ibd\/izae251","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"8020_CR24","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.14309\/ajg.0000000000002947","volume":"119","author":"GS Kochhar","year":"2024","unstructured":"Kochhar GS, Khataniar H, Jairath V, Farraye FA, Desai A (2024) Comparative effectiveness of upadacitinib and tofacitinib in ulcerative colitis: a US propensity-matched cohort study. Am J Gastroenterol 119(12):2471\u20132479. https:\/\/doi.org\/10.14309\/ajg.0000000000002947","journal-title":"Am J Gastroenterol"},{"issue":"35","key":"8020_CR25","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.3748\/wjg.v26.i35.5362","volume":"26","author":"S K\u00e4rnsund","year":"2020","unstructured":"K\u00e4rnsund S, Lo B, Bendtsen F, Holm J, Burisch J (2020) Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol 26(35):5362\u20135374. https:\/\/doi.org\/10.3748\/wjg.v26.i35.5362","journal-title":"World J Gastroenterol"},{"key":"8020_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf063","author":"M Attauabi","year":"2025","unstructured":"Attauabi M, Madsen GR, Holm JP et al (2025) Incidence of osteoporosis and osteopenia in newly diagnosed inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izaf063","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"8020_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.7326\/0003-4819-133-10-200011210-00012","volume":"133","author":"CN Bernstein","year":"2000","unstructured":"Bernstein CN, Blanchard JF, Leslie WD, Wajda A, Yu BN (2000) The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 133(10):795\u2013799. https:\/\/doi.org\/10.7326\/0003-4819-133-10-200011210-00012","journal-title":"Ann Intern Med"},{"issue":"2","key":"8020_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.14309\/ajg.0000000000000062","volume":"114","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Mahl M, Sachs MC et al (2019) Fracture risk in patients with inflammatory bowel disease: a nationwide population-based cohort study from 1964 to 2014. Am J Gastroenterol 114(2):291\u2013304. https:\/\/doi.org\/10.14309\/ajg.0000000000000062","journal-title":"Am J Gastroenterol"},{"key":"8020_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2024.1479928","volume":"5","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li J, Yang G et al (2024) Global burden of inflammatory bowel disease in the elderly: trends from 1990 to 2021 and projections to 2051. Front Aging 5:1479928. https:\/\/doi.org\/10.3389\/fragi.2024.1479928","journal-title":"Front Aging"},{"issue":"6","key":"8020_CR30","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.4414\/smw.2024.3407","volume":"154","author":"A Kreienbuehl","year":"2024","unstructured":"Kreienbuehl A, Rogler G, Emanuel B, Biedermann L, Meier C, Juillerat P, Restellini S, Hruz P, Vavricka SR, Aeberli D, Seibold F (2024Jun 10) Bone health in patients with inflammatory bowel disease. Swiss medical weekly. 154(6):3407. https:\/\/doi.org\/10.4414\/smw.2024.3407","journal-title":"Swiss medical weekly."},{"issue":"2","key":"8020_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/gut.46.2.176","volume":"46","author":"P Vestergaard","year":"2000","unstructured":"Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L (2000) Fracture risk is increased in Crohn\u2019s disease, but not in ulcerative colitis. Gut 46(2):176\u2013181. https:\/\/doi.org\/10.1136\/gut.46.2.176","journal-title":"Gut"},{"issue":"3","key":"8020_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1053\/gast.2003.50106","volume":"124","author":"CN Bernstein","year":"2003","unstructured":"Bernstein CN, Leslie WD, Leboff MS (2003) AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124(3):795\u2013841. https:\/\/doi.org\/10.1053\/gast.2003.50106","journal-title":"Gastroenterology"},{"issue":"11","key":"8020_CR33","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1023\/A:1026650719552","volume":"43","author":"RJ Robinson","year":"1998","unstructured":"Robinson RJ, al-Azzawi F, Iqbal SJ et al (1998) Osteoporosis and determinants of bone density in patients with Crohn\u2019s disease. Dig Dis Sci 43(11):2500\u20132506. https:\/\/doi.org\/10.1023\/A:1026650719552","journal-title":"Dig Dis Sci"},{"key":"8020_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1407692","volume":"15","author":"CL Chen","year":"2024","unstructured":"Chen CL, Wang JY (2024) Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment. Front Endocrinol (Lausanne) 15:1407692. https:\/\/doi.org\/10.3389\/fendo.2024.1407692","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"8020_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-018-0865-3","volume":"13","author":"J Wu","year":"2018","unstructured":"Wu J, Zhang Q, Yan G, Jin X (2018) Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J Orthop Surg Res 13(1):194. https:\/\/doi.org\/10.1186\/s13018-018-0865-3","journal-title":"J Orthop Surg Res"},{"issue":"5","key":"8020_CR36","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1210\/jc.2018-02236","volume":"104","author":"H Lyu","year":"2019","unstructured":"Lyu H, Jundi B, Xu C et al (2019) Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 104(5):1753\u20131765. https:\/\/doi.org\/10.1210\/jc.2018-02236","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"8020_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/gut.2004.044370","volume":"54","author":"AR Moschen","year":"2005","unstructured":"Moschen AR, Kaser A, Enrich B et al (2005) The RANKL\/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54(4):479\u2013487. https:\/\/doi.org\/10.1136\/gut.2004.044370","journal-title":"Gut"},{"issue":"5","key":"8020_CR38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF02563820","volume":"46","author":"HA Morris","year":"1990","unstructured":"Morris HA, Need AG, O\u2019Loughlin PD, Horowitz M, Bridges A, Nordin BE (1990) Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 46(5):305\u2013308. https:\/\/doi.org\/10.1007\/BF02563820","journal-title":"Calcif Tissue Int"},{"key":"8020_CR39","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2147\/DDDT.S148654","volume":"13","author":"ZA Yanbeiy","year":"2019","unstructured":"Yanbeiy ZA, Hansen KE (2019) Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther 13:2843\u20132852. https:\/\/doi.org\/10.2147\/DDDT.S148654","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"8020_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Pannacciulli N et al (2017) <article-title update=\"added\">10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"8020_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.cgh.2012.10.022","volume":"11","author":"LE Targownik","year":"2013","unstructured":"Targownik LE, Bernstein CN, Nugent Z, Leslie WD (2013) Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol 11(3):278\u2013285. https:\/\/doi.org\/10.1016\/j.cgh.2012.10.022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"8020_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/aje\/kwf007","volume":"156","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn\u2019s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156(1):1\u201310. https:\/\/doi.org\/10.1093\/aje\/kwf007","journal-title":"Am J Epidemiol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08020-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:07:23Z","timestamp":1792271243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08020-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8020"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08020-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AD, HB, HK: none exist. JGH: Advisory Board BMS. FAF: consultant for AbbVie, Astellas, Bausch, Biocon, BMS, Braintree Labs, Fresenius Kabi, GI Reviewers, GSK, IBD Educational Group, Iterative Health, Janssen, Pharmacocosmos, Pfizer, Sandoz and Viatris. He sits on a DSMB for Lilly. GSK: Speaker: Eli Lilly Pharma. Advisory Board: GIE Medical, Eli Lilly Pharma, Consultant: Pentax endoscopy, Olympus endoscopy, Boston Scientific endoscopy, Takeda Pharmaceuticals. Stock Options: Digbi Health. MR: Advisory Boards and Consultant (both) for Abbvie, Johnson and Johnson, UCB, Takeda, Pfizer, BMS, Organon, Amgen, Genentech, Gilead, Salix, Prometheus, Lilly, Celgene, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celltrion, Roche, Merck, Sanofi, Biocon, Abavax. ML: consulting\u2014AbbVie, Janssen, Lilly, Bristol Myers Squibb, Pfizer, Takeda, Prometheus, Celltrion, Intecept, Roivant, Target RWE; research support\u2014Pfizer, Takeda, Lilly.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}